Axovant Sciences Ltd (AXON) Receives Consensus Rating of “Hold” from Analysts
Axovant Sciences Ltd (NASDAQ:AXON) has earned an average recommendation of “Hold” from the fifteen research firms that are covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a sell rating, five have assigned a hold rating and six have issued a buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $13.61.
AXON has been the topic of a number of recent research reports. Oppenheimer reissued a “buy” rating and set a $30.00 target price on shares of Axovant Sciences in a research report on Monday, September 25th. Jefferies Group set a $40.00 target price on shares of Axovant Sciences and gave the stock a “buy” rating in a research report on Friday, August 25th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Axovant Sciences in a report on Wednesday, September 27th. BidaskClub raised shares of Axovant Sciences from a “sell” rating to a “hold” rating in a report on Thursday, October 5th. Finally, Robert W. Baird reaffirmed a “hold” rating and issued a $6.00 price target on shares of Axovant Sciences in a report on Wednesday, November 1st.
Shares of Axovant Sciences (NASDAQ:AXON) opened at $5.03 on Thursday. The company has a quick ratio of 5.94, a current ratio of 5.94 and a debt-to-equity ratio of 0.34. Axovant Sciences has a 52 week low of $4.60 and a 52 week high of $27.98.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.